SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

ritonavir

ENTA·ENANTA PHARMACEUTICALS INC
NEUTRAL
Drug Impact Rating2/10
Trial phase
Approved (generic, off-patent)
Time to market
Already on market since 1996 (Norvir); generic widely available.
Why 2/10
Ritonavir is an old, generic, off-patent drug that Enanta does not develop, own, or commercialize. There is no upcoming hard, dated catalyst for ritonavir. The two patent-litigation events tied to ritonavir-containing products (US Federal Circuit ruling in June 2026 and UPC ruling on October 29, 2026) have already occurred and were negative for Enanta. With no pending binary catalyst for this drug, the impact score is low.
Actionable Insight NEUTRAL

Ritonavir itself is not an Enanta catalyst. The two patent-litigation "lottery tickets" tied to ritonavir-containing products have now both come up empty: the US patent was invalidated in June 2026 and the EU patent was revoked on October 29, 2026. Enanta's next meaningful binary catalyst is the Phase 2b data readout from the RESOLVE trial of zelicapavir for RSV, expected in 2027. The company also reports fiscal Q4 2026 earnings on November 16, 2026, which will show the continuing trajectory of its declining HCV royalty revenue.

Price Chart

Loading chart...

Executive Summary

Ritonavir is an old, widely genericized HIV protease inhibitor (brand name Norvir, originally by Abbott/AbbVie) that is not a drug Enanta Pharmaceuticals develops, owns, or commercializes. Enanta's connection to ritonavir is indirect: (1) historically, Enanta-discovered HCV protease inhibitors were co-formulated with ritonavir as a pharmacokinetic booster in AbbVie's now-obsolete hepatitis C products Technivie and Viekira Pak/Xr; and (2) Enanta sued Pfizer alleging Paxlovid (nirmatrelvir co-packaged with ritonavir) infringed its patents. Enanta lost that litigation on both sides of the Atlantic: the US Federal Circuit affirmed patent invalidity in June 2026, and the Unified Patent Court revoked the European counterpart on October 29, 2026, just one day before this report. Enanta's current business is focused on its own RSV pipeline (zelicapavir in Phase 2b/3, EDP-323 in Phase 2) and immunology programs, with revenue from declining HCV royalties on AbbVie's MAVYRET/MAVIRET (which does not contain ritonavir).

How It Works

Ritonavir is an HIV protease inhibitor, meaning it blocks a viral enzyme the HIV virus needs to replicate. In modern practice it is used almost exclusively as a "booster" (pharmacokinetic enhancer) at low doses: it inhibits a liver enzyme (CYP3A4) that would otherwise break down other antiviral drugs, raising their blood levels and allowing lower, less frequent dosing. This boosting role is why ritonavir appears as a component in several combination products, including AbbVie's former HCV regimens and Pfizer's COVID-19 antiviral Paxlovid.

Trial Status

Ritonavir was first approved by the FDA in 1996 as Norvir for HIV/AIDS. It is now off-patent and widely available as a generic. It is not an active development candidate at Enanta or any other company; its role is as an established pharmacokinetic booster in fixed-dose combination products developed by other firms.

The Two-Sided Case

▲ Bull Case3
Enanta's historical partnership with AbbVie demonstrated its drug discovery capabilities: Enanta-discovered HCV protease inhibitors were part of multi-billion-dollar franchise products (Viekira, MAVYRET).
The now-resolved Paxlovid patent litigation, while unsuccessful, highlighted that Enanta's research into coronavirus protease inhibitors was early and scientifically legitimate, validating its chemistry platform.
With the litigation overhang removed, investor attention can now focus entirely on Enanta's RSV pipeline (zelicapavir, EDP-323), which represents the company's actual value proposition.
▼ Bear Case3
Enanta's two patent-infringement cases against Pfizer over Paxlovid (which contains ritonavir) both failed: the US Federal Circuit invalidated the patent in June 2026 and the UPC revoked the European counterpart on October 29, 2026, eliminating any potential royalty stream from Paxlovid sales.
Enanta's revenue is entirely dependent on declining HCV royalties from AbbVie's MAVYRET/MAVIRET, which fell 21% year-over-year to $14.4 million in fiscal Q3 2026. This revenue stream does not involve ritonavir and is in structural decline as the HCV cured-patient pool shrinks.
The company has no approved products of its own and is a clinical-stage biotech burning cash ($19.5 million net loss in Q3 2026), with its pipeline focused on unproven RSV treatments facing a competitive landscape that includes approved vaccines and therapies from larger players.

Upcoming Catalysts

  • No upcoming catalysts for ritonavir itself. Enanta's next catalysts are: fiscal Q4 2026 earnings (November 16, 2026) and Phase 2b data from the zelicapavir RESOLVE RSV trial (expected 2027).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ENANTA PHARMACEUTICALS INC 8-K ENTA ·Originating report

Sources · 10

Hover a chip for the title
1 en.wikipedia.org2 ir.enanta.com3 cafc.uscourts.gov4 ir.enanta.com5 biotechdistilled.substack.com6 stocktitan.net7 ir.enanta.com8 ir.enanta.com9 enanta.com10 sec.gov